This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
iCAD, Inc. (Nasdaq:ICAD), industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that Chief Financial Officer (CFO), Kevin Burns, has been named iCAD’s Chief Operating Officer (COO). In this newly-created position, Burns will lead and manage all operational functions within the Company in addition to continuing his role as CFO.
“Kevin has made many significant contributions to iCAD and I am confident he will continue to guide the Company in meeting its short and long term growth and business goals. During his tenure as CFO, the Company’s financial performance has improved through increasing efficiencies and maximizing investments, while reducing operating expenses,” said Ken Ferry, President and CEO of iCAD. “Kevin has played a critical role in developing our strategic partnerships, which have resulted in a stronger overall growth trajectory in our cancer detection and Xoft therapy businesses. We expect his expanded executive role will enhance our continued success.”
“I’m looking forward to taking on these additional responsibilities at iCAD and continuing to work closely with our executive team, as we advance the Company to its next level of growth,” said Kevin Burns, COO and CFO of iCAD. “This is an exciting time for our Company, as we successfully broaden our product offerings, build our customer base and expand our reach through technology innovation and strategic partnerships.”
About iCAD, Inc.
iCAD is an industry-leading provider of Computer-Aided Detection (CAD) technologies, advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. iCAD offers a comprehensive range of high-performance, upgradeable CAD solutions for mammography and advanced image analysis and workflow solutions for Magnetic Resonance Imaging, for breast and prostate cancers and Computed Tomography for colorectal cancer. iCAD’s Xoft System, offers radiation treatment for early-stage breast cancer that can be administered in the form of Intraoperative Radiation Therapy or accelerated partial breast irradiation. The Xoft System is also cleared for the treatment of non-melanoma skin cancer and gynecological cancers. For more information, call (877) iCADnow, or visit
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the Company’s ability to defend itself in litigation matters, the risks relating to the Company’s acquisition of Xoft including, the expected benefits of the acquisition may not be achieved in a timely manner, or at all; the Xoft business operations may not be successfully integrated with iCAD’s and iCAD may be unable to achieve the expected synergies, business and strategic objectives following the transaction, the risks of uncertainty of patent protection; the impact of supply and manufacturing constraints or difficulties; product market acceptance; possible technological obsolescence; increased competition; customer concentration; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “anticipate”, “likely”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov